NO801469L - Pyrimidinforbindelser og fremgangsmaate til deres fremstilling - Google Patents

Pyrimidinforbindelser og fremgangsmaate til deres fremstilling

Info

Publication number
NO801469L
NO801469L NO801469A NO801469A NO801469L NO 801469 L NO801469 L NO 801469L NO 801469 A NO801469 A NO 801469A NO 801469 A NO801469 A NO 801469A NO 801469 L NO801469 L NO 801469L
Authority
NO
Norway
Prior art keywords
pyrimid
procedures
compounds
preparation
pyrimid compounds
Prior art date
Application number
NO801469A
Other languages
English (en)
Norwegian (no)
Inventor
Adrian Marxer
Kurt Eichenberger
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of NO801469L publication Critical patent/NO801469L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO801469A 1979-05-18 1980-05-16 Pyrimidinforbindelser og fremgangsmaate til deres fremstilling NO801469L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH466979 1979-05-18

Publications (1)

Publication Number Publication Date
NO801469L true NO801469L (no) 1980-11-19

Family

ID=4280399

Family Applications (1)

Application Number Title Priority Date Filing Date
NO801469A NO801469L (no) 1979-05-18 1980-05-16 Pyrimidinforbindelser og fremgangsmaate til deres fremstilling

Country Status (21)

Country Link
EP (1) EP0019811A1 (fr)
JP (1) JPS55154971A (fr)
KR (1) KR830002757A (fr)
AR (1) AR228256A1 (fr)
AU (1) AU5848480A (fr)
DD (1) DD150609A5 (fr)
DK (1) DK214480A (fr)
ES (1) ES491514A0 (fr)
FI (1) FI801600A7 (fr)
GB (1) GB2052487B (fr)
GR (1) GR68453B (fr)
IE (1) IE49803B1 (fr)
IL (1) IL60086A (fr)
MA (1) MA18829A1 (fr)
NO (1) NO801469L (fr)
NZ (1) NZ193730A (fr)
OA (1) OA06533A (fr)
PL (1) PL224313A1 (fr)
PT (1) PT71251A (fr)
ZA (1) ZA802909B (fr)
ZW (1) ZW11880A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4507146A (en) * 1982-12-28 1985-03-26 Ciba-Geigy Corporation 2,4-Diamino-6-halo-5-trifluoromethylpyrimidines having herbicidal activity
DE3829469A1 (de) * 1988-08-31 1990-03-01 Bayer Ag Verfahren zur herstellung von substituierten n-azinyl-n'-sulfonyl-isothioharnstoffen und n-azinyl-iminodithiokohlensaeure-s,s-diester als zwischenprodukte zu ihrer herstellung
AU9302298A (en) * 1997-09-03 1999-03-22 Eli Lilly And Company Pyrimidine derivatives
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DK1318997T3 (da) 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
CZ20032341A3 (cs) * 2001-01-31 2004-12-15 Synaptic Pharmaceutical Corporation Použití antagonistů GAL3 receptoru pro léčbu deprese a/nebo úzkosti
KR20040099324A (ko) 2002-03-13 2004-11-26 유로-셀티큐 에스.에이. 아릴 치환된 피리미딘 및 이것의 용도
ATE366045T1 (de) * 2002-03-15 2007-07-15 Ciba Sc Holding Ag Verwendung von 4-aminopyrimidinen zur antimikrobiellen behandlung von oberflächen
ATE468336T1 (de) 2002-03-15 2010-06-15 Vertex Pharma Azolylaminoazine als proteinkinasehemmer
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
DE60308387T2 (de) 2002-08-02 2007-09-20 Vertex Pharmaceuticals Inc., Cambridge Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
WO2004072029A2 (fr) 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Compositions utiles en tant qu'inhibiteurs de proteine kinases
AU2006279376B2 (en) 2005-08-18 2011-04-14 Vertex Pharmaceuticals Incoporated Pyrazine kinase inhibitors
TW200734327A (en) 2005-11-03 2007-09-16 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
WO2008057940A1 (fr) 2006-11-02 2008-05-15 Vertex Pharmaceuticals Incorporated Aminopyridines et aminopyrimidines utiles en tant qu'inhibiteurs de protéines kinases
WO2008077086A1 (fr) 2006-12-19 2008-06-26 Vertex Pharmaceuticals Incorporated Aminopyridines utiles comme inhibiteurs de protéine kinases
WO2008112642A1 (fr) 2007-03-09 2008-09-18 Vertex Pharmaceuticals Incorporated Aminopyrimidines utiles en tant qu'inhibiteurs des protéines kinases
EP2134709A1 (fr) 2007-03-09 2009-12-23 Vertex Pharmaceuticals, Inc. Utilisation des aminopyridines comme inhibiteurs de protéines kinases
EP2137183B1 (fr) 2007-03-09 2011-09-28 Vertex Pharmaceuticals Incorporated Aminopyrimidines utiles en tant qu'inhibiteurs des protéines kinases
JP2010523700A (ja) 2007-04-13 2010-07-15 バーテックス ファーマシューティカルズ インコーポレイテッド キナーゼインヒビターとして有用なアミノピリミジン
CN101801959A (zh) 2007-05-02 2010-08-11 沃泰克斯药物股份有限公司 可用作激酶抑制剂的氨基嘧啶类化合物
CN101679378A (zh) 2007-05-02 2010-03-24 沃泰克斯药物股份有限公司 用作激酶抑制剂的噻唑和吡唑
AR067762A1 (es) 2007-07-31 2009-10-21 Vertex Pharma Proceso para preparar 5-fluoro-1h-pirazolo (3,4-b) piridin-3-amina y derivados de la misma
AU2009288200A1 (en) 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
WO2010077613A1 (fr) * 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulateurs de récepteurs de type toll (tlr)
KR102328682B1 (ko) 2018-08-27 2021-11-18 주식회사 대웅제약 신규한 헤테로사이클릭아민 유도체 및 이를 포함하는 약학 조성물
EP4243826A1 (fr) * 2020-11-12 2023-09-20 3Z Ehf Nouveaux traitements du trouble du déficit de l'attention/hyperactivité

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE754832A (fr) * 1969-08-14 1971-02-15 Beecham Group Ltd Iminazolines

Also Published As

Publication number Publication date
PL224313A1 (fr) 1981-02-13
JPS55154971A (en) 1980-12-02
IL60086A0 (en) 1980-07-31
DD150609A5 (de) 1981-09-09
MA18829A1 (fr) 1980-12-31
DK214480A (da) 1980-11-19
ES8104279A1 (es) 1981-04-16
PT71251A (en) 1980-06-01
EP0019811A1 (fr) 1980-12-10
GB2052487A (en) 1981-01-28
AR228256A1 (es) 1983-02-15
IL60086A (en) 1984-03-30
ZA802909B (en) 1981-05-27
AU5848480A (en) 1980-11-20
OA06533A (fr) 1981-07-31
FI801600A7 (fi) 1981-01-01
ES491514A0 (es) 1981-04-16
ZW11880A1 (en) 1980-12-17
KR830002757A (ko) 1983-05-30
IE801023L (en) 1980-11-18
GB2052487B (en) 1983-05-11
IE49803B1 (en) 1985-12-25
NZ193730A (en) 1982-12-21
GR68453B (fr) 1981-12-30

Similar Documents

Publication Publication Date Title
NO801469L (no) Pyrimidinforbindelser og fremgangsmaate til deres fremstilling
NO813804L (no) Substituerte pyrimidiner og fremgangsmaate for deres fremstilling
DK211382A (da) Cephalosporinderivater og fremgangsmaade til deres fremstilling
DK338379A (da) Pyrazinderivater og fremgangsmaade til deres fremstilling
DK3880A (da) Fremgangsmaade til fremstilling af peptidylargininaldehydderivater og disses anvendelse
DK43981A (da) Kompositmaterialer og fremgangsmaade til deres fremstilling
DK446982A (da) Cyanosteroider og fremgangsmaade til deres fremstilling
DK149623C (da) Fremgangsmaade til fremstilling af alfa-hydroxycarboxylsyreamider
DK153791C (da) Fremgangsmaade til fremstilling af 7-hydroxycumaraner
DK345977A (da) G rifamycinforbindelser og fremgangsmaade til deres fremstillin
DK401882A (da) Cyclopentadienderivater og fremgangsmaader til deres fremstilling
DK159851C (da) Fremgangsmaade til fremstilling af riboflavin
DK251281A (da) N6-adenosiner og fremgangsmaader til deres fremstilling
NO780800L (no) Azoforbindelser og fremgangsmaate til deres fremstilling
DK409277A (da) Pentapeptider og fremgangsmaade til deres fremstilling
DK81380A (da) Fremgangsmaade til indramning
DK63080A (da) 25-hydroxy-24-oxochlostanderivater og fremgangsmaade til fremstilling deraf
DK308878A (da) Aminoglyosidderivater og fremgangsmaader til deres fremstilling
IT8048889A0 (it) Composti perfluoroalchilici e procedimento per prepararli
DK111678A (da) Enzym-marumer og fremgangsmaade til deres fremstilling
DK243380A (da) Praeformede banelignende strukturer og fremgangsmaade til deres fremstilling
NO790047L (no) Kompoundmaterialer og fremgangsmaate til deres fremstilling
DK24280A (da) Spiro-quinolylhydantoiner fremgangsmaade til deres fremstilling og deres anvendelse
DK21579A (da) 5-phenethyl-2-oxazolidon-derivater og fremgangsmaade til deres fremstilling
DK416278A (da) 2-oxazolidon-derivater og fremgangsmaade til deres fremstilling